![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, August 04, 2021 12:28:45 AM
<<<<<< If the studies were good enough for the FDA to clear, why not good enough for insurance companies? >>>>>>>
Similar to the NHS local CCGs refusing to authorize doctors to prescribe ActiPatch, an NHS approved medical device, insurance companies are slow to adopt new treatments.
Even with BIEL demonstrating how ActiPatch use would lower patient use of medical care and therefor save CCGs/Insurers money they resist. They have a business model set up around 'a drug for every problem' and are evidently satisfied with the results despite the side effects, one of those being 600,000 opioid deaths.
After one Clearance for eyelid surgery the FDA dragged their feet for 13 years before reclassifying ActiPatch from a Class 3 Device, life sustaining products, to the less regulated Class 2 Device. So the FDA also has a history of maintaining the status quo.
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM